Moreover, it has been suggested that KRAS mutant NSCLC should not be overlooked as the most common oncogenic mutation in lung cancer, as incidences of such mutations have also been identified in subclonal populations, therefore indicating that the KRAS mutant NSCLC should be analyzed as a completely different subgroup of lung cancers [44]. The gene discussed is KRAS; the disease is lung cancer.